A new clinical trial explored whether raising cellular NAD⁺ levels with high-dose nicotinamide riboside could influence lingering neurological and physical symptoms in long-COVID. Millions of people ...
Khaleej Times on MSN
2PointZero Group to adopt dividend policy in 2027, with 35% YoY growth target
Ahead of the completion of Multiply Group’s strategic acquisition of 2PointZero and Ghitha Holding, which remains subject to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback